中科信息(300678.SZ):引入的醫療腦機接口技術,主要用於智慧麻醉、智慧康復兩大應用場景
格隆匯5月19日丨中科信息(300678.SZ)於2023年5月18日接待投資者實現參觀、交流,交流環節中,就“在智慧醫療方面,公司腦機接口方面的項目進程是怎樣的?”,公司回覆稱,公司引入的醫療腦機接口技術,主要用於智慧麻醉、智慧康復兩大應用場景,以進一步完善公司智慧醫療整體解決方案。智慧麻醉應用場景方面,正在開展麻醉深度監測腦機接口設備選型;智慧康復應用場景方面,引進的腦機接口設備已到位,目前正在與四川大學華西醫院相關專家設計動物實驗方案。公司申報的“腦認知與智慧醫療創新應用實驗室”在2022年也獲得公示。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.